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The effect of low molecular weight heparin (LMWH) with or without antithrombin III (AT III)
has been studied in a rabbit model of disseminated intravascular coagulation (DIC) in-
duced by continuous infusion of 100 µg/kg/hr of Escherichia coli endotoxin for 6 hr.
LMWH (5 and 10 IU/kg/hr/6 hr), alone or in combination with AT III (20 U/kg/hr/6 hr), or
saline were administered simultaneously with endotoxin. Hemostatic markers at 0, 2, and
6 hr as well as kidney fibrin deposits and the mortality rate at 24 hr were determined.
Rabbits receiving only endotoxin showed an impairment in hemostasis, as well as high
kidney fibrin deposits and a high mortality rate. LMWH alone did not exert any effect. The
simultaneous infusion of LMWH and AT III exerted a beneficial effect on the hemostatic
markers and reduced the kidney fibrin deposits as well as the mortality rate in a LMWH
dose-dependent manner. Fibrinogen and protein C consumption were significantly
higher and renal fibrin deposits more intense in the rabbits that had died in the first 24 hr.
There was also a significant positive correlation between kidney fibrin deposits and
platelets, fibrinogen, and protein C consumption, taking the whole rabbit population. It is
concluded that the simultaneous infusion of LMWH and AT III is useful in this DIC model
and would make it possible to reduce significantly the AT III doses used when AT III is
given alone. Am. J. Hematol. 60:6–11, 1999. © 1999 Wiley-Liss, Inc.
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INTRODUCTION
Disseminated intravascular coagulation (DIC) is a se-
rious and frequent complication of gram-negative bacte-
rial sepsis [1]. Despite the use of potent antibiotics and
intensive supportive care, the mortality among patients
with sepsis-induced DIC remains close to 60% [2].
Gram-negative bacteria include in their outer mem-
brane a molecule called endotoxin or lipopolysaccharide.
Endotoxin leads monocytes and endothelial cells to gen-
erate several cytokines that in turn activate coagulation,
mainly by the extrinsic pathway [3]. As a result, higher
than normal amounts of thrombin are generated. Throm-
bin transforms fibrinogen into fibrin and stimulates plate-
let aggregation, both actions leading to the formation of
stable microthrombi. The exhaustion of antithrombin III
(AT III) and protein C, the main coagulation inhibitors,
could perpetuate fibrin generation [4,5], thus allowing
the appearance of microvascular thrombi in various or-
gans and subsequent multiple organ failure (MOF) [6].
Therefore, treatment strategies aimed at keeping suitable
levels of the coagulation inhibitors could be an interest-
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ing approach to develop more efficient therapeutic
schedules.
Heparin, which accelerates coagulation inhibition by
acting as a cofactor of AT III, has not been as effective
as expected when used as a treatment in endotoxin-
induced DIC [7]. The most likely explanation is that AT
III is consumed during DIC, thus rendering useless the
subsequent administration of low molecular weight hep-
arin (LMWH). To our knowledge, there are no studies
describing the effects of LMWH on endotoxin-induced
DIC. However, LMWH has proved as efficient as un-
fractionated heparin (UFH), or better, in other thrombotic
disorders [8,9]. On the other hand, although the infusion
of AT III in experimental models of DIC has yielded
promising results [10–14], this treatment has only been
effective when supratherapeutic doses have been used
[15]. Therefore, a therapeutic approach that keeps plasma
AT III levels at a suitable concentration to allow the
action of LMWH may be of interest.
The aim of the present work has been to evaluate the
effect of different doses of LMWH with or without AT
III in a rabbit model of endotoxin-induced DIC. Kidney
fibrin deposits and mortality have been assessed and their
relationship to hemostatic parameters is reported.
MATERIALS AND METHODS
Experimental Model
Male New Zealand white rabbits (weight, 2–3 kg)
were used. Animals were anesthetized by an intramus-
cular injection of 30 mg/kg ketamin hydrochloride and 2
× 10−3 mg/kg xylacine hydrochloride followed by intra-
muscular boosts of ketamin hydrochloride throughout the
experiment. DIC was induced in rabbits by 100 mg/kg/hr
endotoxin (Escherichia coli 0111:B4, Difco Laborato-
ries, Detroit, MI) for 6 hr in 60 ml (10 ml/hr) saline given
intravenously through the marginal ear vein.
Treatments were started simultaneously with endotox-
in infusion through the contralateral marginal ear vein.
Six different groups were established: 1. Low-dose
LMWH group (n 4 18) were given five anti-factor Xa
international units (IU)/kg/hr Dalteparin (Pharmacia &
Upjohn, Sweden) for 6 hr in 60 ml (10 ml/hr) of saline;
2. High-dose LMWH group (n 4 16) were given 10
anti-factor Xa IU/kg/hr Dalteparin for 6 hr in 60 ml (10
ml/hr) of saline; 3. Low-dose LMWH plus AT III group
(n 4 10) were given the lower Dalteparin dose (5 IU/
kg/hr/6 hr) plus 20 U/kg/hr/6 hr AT III (Kybernin-P,
Centeon SA, Marburg, Germany) in 60 ml (10 ml/hr) of
saline; 4. High-dose LMWH plus AT III group (n 4 10)
were given the higher Dalteparin dose (10 IU/kg/hr/6 hr)
plus 20 U/kg/hr/6 hr AT III in 60 ml (10 ml/hr) of saline;
5. Endotoxin control group (n 4 10) was infused with
saline as placebo (10 ml/hr) for 6 hr; and 6. Ten rabbits
that were given neither endotoxin nor treatment were
infused with saline (10 ml/hr by both marginal ear veins
for 6 hr) as an additional control group.
Surviving rabbits were sacrificed 24 hr after the start
by intravenous injection of 60 mg/kg Nembutal (Abbot
Laboratories, Abbot Park, IL). Kidneys were extracted
from all animals (survivors and nonsurvivors) for subse-
quent histological studies.
Laboratory Methods
Blood samples were taken through a catheter inserted
into a femoral artery before starting the endotoxin infu-
sion, and 2 and 6 hr afterward. Blood samples (9 vol.)
were collected in 3.2% citrate (1 vol.). Blood samples
were kept on ice no longer than 2 hr to determine fi-
brinogen, AT III and protein C activity. Platelet-poor
plasma was obtained by centrifugation at 1,600 g for 20
min at 4°C in a Hermle Z 382 K centrifuge (Hermle
Labortechnik GmbH, Wehingen, Germany) and stored at
−70°C until assay. Tubes containing K3-EDTA were
used to collect blood for platelet counts.
Platelets were determined in a Counter STKS auto-
matic analyzer (Coulter Corp., Hialeah, FL). Fibrinogen
was measured following the Clauss method [16]. AT III
activity was measured by an amidolytic assay (Coamatic
Antithrombin III, Chromogenix, Stockholm, Sweden)
[17]. Protein C activity was determined using a commer-
cially available assay (Coamatic Protein C, Chromoge-
nix) [18].
Histological Examination
Kidney sections were fixed in formalin, embedded in
paraffin, stained with Masson’s trichrome and examined
for the presence of fibrin microthrombi by a pathologist
unaware of the experimental design. Tissue sections were
scored on a scale from 0 to 4 as previously described
[14]. Briefly: (0) no fibrin; (1) partial fibrin deposits in
some glomeruli; (2) partial deposits in all glomeruli; (3)
large quantities of fibrin in all glomeruli; and (4) fibrin
thrombi in glomerular capillaries and in noncapillary
vessels.
Data Analysis
Results at 2 and 6 hr were converted to percentages
assuming a value of 100% for basal data, and expressed
as mean ± SEM. The Student’s t-test was used to look for
differences in hemostatic parameters between endotoxin
control and saline control groups. One-way ANOVA for
multiple comparisons followed by the Tukey B test was
applied to compare the hemostatic parameters between
endotoxin control and treatment groups. The Kruskal-
Wallis test followed by the Mann-Whitney U test was
used to compare fibrin deposits between endotoxin con-
trol and treatment groups. Differences in fibrin deposits
between survivor and nonsurvivor animals were assessed
by the Mann-Whitney U test. Differences in mortality
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rate at 24 hr were assessed by Fisher’s exact test. Dif-
ferences in hemostatic parameters between surviving and
nonsurviving animals were determined by the Student’s
t-test. Possible correlations between kidney fibrin depos-
its and hemostatic parameters were analyzed by the
Spearman rank correlation test.
RESULTS
Effects of LMWH and LMWH Plus AT III on
Endotoxin-Induced Changes in Coagulation
Table I shows the baseline plasma levels of the differ-
ent coagulation parameters in the saline control, endo-
toxin control, and treated groups. In the control group of
rabbits without endotoxin, no changes in the analyzed
parameters were observed (not shown).
Table II shows the plasma levels, expressed in per-
centages with respect to the basal value which is assumed
to be 100%, of the different coagulation parameters ana-
lyzed throughout the experiment in the endotoxin control
and treated groups.
Infusion of endotoxin into rabbits caused a significant
decrease, with respect to the saline group, in platelets and
protein C at 2 hr (P < 0.01) and in platelets, fibrinogen,
protein C (P < 0.001) and AT III (P < 0.05) at 6 hr.
Infusion of both low and high LMWH doses had little
effect on coagulation parameters, showing only a lower
decrease in platelets at 2 and 6 hr in the low-dose LMWH
group (P < 0.05).
However, the simultaneous infusion of LMWH and
AT III remarkably improved the hemostatic profile in the
rabbits that received this treatment with respect to the
endotoxin control group; in addition to an improve-
ment in platelets and fibrinogen, the AT III levels
were kept at a level similar to baseline when low-dose
LMWH was used and significantly increased when this
treatment was applied with high-dose LMWH (Fig. 1A).
Moreover, a remarkable reduction in the protein C con-
sumption was assessed (Fig. 1B), such effect being more
marked again when LMWH was given at high dose (P <
0.01 at 2 and 6 hr) than when low dose was used (P <
0.05 at 6 hr).
Histological Findings
Intense fibrin deposits were detected in the endotoxin
control group, even in noncapillary vessels. The average
value according to the scale described above was 2.61 ±
0.34, which is significantly higher (P 4 0.0078) than the
value obtained in rabbits given saline without endotoxin
(score 0). Low-dose LMWH plus AT III significantly
reduced fibrin deposits in kidneys (score 0.65 ± 0.36, P
4 0.005). At high-dose LMWH plus AT III a dramatic
improvement in renal deposits was found, and no fibrin
was detected in any rabbits (score 0, P < 0.001). How-
TABLE II. Hemostatic Parameters at Two and Six Hr After Endotoxin Infusion in the Endotoxin Control and Treatment Groups†
Group Platelets (%) Fibrinogen (%) AT III (%) Protein C (%)
Endotoxin control 2 hr 48.8 ± 4.6 95.5 ± 3.9 87.7 ± 3.9 58.6 ± 5.2
6 hr 20.3 ± 3.5 58.2 ± 5.1 73.1 ± 5.8 15.1 ± 3.3
LMWH (5 IU/kg/hr) 2 hr 70.9 ± 5.0* 89.0 ± 7.0 94.6 ± 7.8 83.6 ± 11.3
6 hr 40.6 ± 4.8* 65.5 ± 7.5 72.7 ± 4.7 27.4 ± 6.4
LMWH (10 IU/kg/hr) 2 hr 65.7 ± 3.9 82.5 ± 4.1 85.2 ± 5.2 70.4 ± 3.3
6 hr 41.0 ± 7.2* 59.0 ± 4.8 76.9 ± 5.2 18.2 ± 5.7
LMWH (5 IU/kg/hr) + AT III (20 U/kg/hr) 2 hr 62.0 ± 5.4 92.5 ± 5.1 102.0 ± 3.2** 72.2 ± 4.2
6 hr 44.1 ± 5.4** 83.5 ± 5.7** 101.7 ± 5.5** 40.7 ± 6.2*
LMWH (10 IU/kg/hr) + AT III (20 U/kg/hr) 2 hr 61.4 ± 3.8 85.5 ± 6.9 187.3 ± 74.2* 85.6 ± 3.6**
6 hr 47.6 ± 4.7 76.1 ± 7.4 227.6 ± 84.4** 60.9 ± 6.0**
†Data shown as mean ± SEM percent of the basal value. AT III, antithrombin III; LMWH, low molecular weight heparin.
*P < 0.05.
**P < 0.01 as compared with the endotoxin control group.
TABLE I. Hemostatic Parameters at Baseline in the Six Groups of Rabbits*
Group Platelets (× 109/l) Fibrinogen (mg/dl) AT III (%) Protein C (%)
Saline 473.0 ± 47.1 201.3 ± 16.7 99.4 ± 3.2 106.1 ± 6.4
Endotoxin control 454.2 ± 40.8 247.5 ± 31.4 117.9 ± 3.0 112.4 ± 5.0
LMWH (5 IU/kg/hr) 501.4 ± 35.9 217.5 ± 29.6 101.4 ± 6.5 85.8 ± 6.8
LMWH (10 IU/kg/hr) 481.4 ± 34.4 200.1 ± 12.8 118.9 ± 7.4 98.7 ± 5.3
LMWH (5 IU/kg/hr) + AT III (20 U/kg/hr) 407.5 ± 21.3 224.0 ± 25.1 113.7 ± 3.7 112.6 ± 10.4
LMWH (10 IU/kg/hr) + AT III (20 U/kg/hr) 435.0 ± 29.2 229.5 ± 18.0 90.9 ± 10.9 105.6 ± 11.3
*Data shown as mean ± SEM. AT III, antithrombin III; LMWH, low molecular weight heparin.
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ever, neither low nor high LMWH doses without AT III
had any significant effect on the extent of fibrin deposi-
tion (score 2.02 ± 0.34 and 1.71 ± 0.31) (Fig. 2).
Taking all the animals together except the saline con-
trol group (n 4 64), a significant positive correlation
between protein C consumption at 2 and 6 hr and kidney
fibrin deposition was observed (r 4 0.29, P < 0.05 and
r 4 0.56, P < 0.001, respectively). There was also a
positive correlation between kidney fibrin deposits and
the decrease in platelets and fibrinogen at 6 hr (r 4 0.33
and r 4 0.36, P < 0.001).
Mortality Rate
Seven of 10 rabbits (70%) died in the first 24 hr fol-
lowing endotoxin infusion in the endotoxin control
group, whereas none of the saline control group animals
died. Both LMWH doses infused alone did not remark-
ably reduce the mortality rate: Nine of 18 rabbits (50%)
died at low dose and seven of 16 rabbits (44%) died at
high dose; however, when AT III and LMWH were si-
multaneously infused, mortality decreased to 30% (three
of 10 rabbits) at low LMWH dose and 20% (two of 10
rabbits) at high LMWH dose, the latter not reaching sta-
tistical significance with respect to the endotoxin control
group (P 4 0.06), probably due to the relatively low
number of animals studied.
Taking again all the animals together except the saline
control group, a significantly more pronounced decrease
was found in plasma protein C activity at 6 hr in animals
that died (n 4 28) with respect to survivors (n 4 36)
(22.0 ± 4.3 vs. 37.3 ± 4.5, P < 0.05); platelet drop and
fibrinogen consumption were also higher at 6 hr in non-
surviving rabbits (32.5 ± 3.5 vs. 44.5 ± 3.8, P < 0.05 and
55.0 ± 2.9 vs. 76.9 ± 4.4, P < 0.001, respectively); as
expected, nonsurvivors showed significantly more in-
tense renal fibrin deposits (2.75 ± 0.36 vs. 1.59 ± 0.29, P
< 0.001).
DISCUSSION
AT III consumption in patients with shock and DIC
seems to play an important pathological role, and the
benefits of a substitution therapy with AT III in these
patients have been accurately reviewed [19]. In this study
we report the effect of LMWH given alone or together
with AT III on endotoxin-induced DIC in rabbits. Ad-
ministration of endotoxin in our model resulted in severe
DIC as shown by the marked decrease in platelets, fi-
brinogen, AT III, and protein C, which is in agreement
with previous clinical and experimental studies. More-
over, intense renal fibrin deposition and a high mortality
rate were assessed as a result of the endotoxin infusion.
LMWHs, which are mixtures of structurally and func-
tionally heterogeneous polysaccharide chains, are antico-
agulants broadly used in different human clinical condi-
tions related to thrombotic phenomena, which exert their
action by enhancing the inhibitory capacity of AT III
against factor Xa and thrombin [20]. When LMWH was
infused without AT III there were no beneficial effects
either on hemostatic parameters or on renal fibrin depo-
sition or mortality. These results concur with those of
previous studies showing that UFH alone is useless in the
same model of endotoxin-induced DIC [14]. The marked
AT III decrease, mainly due to consumption during com-
plex formation with activated clotting factors but also to
inactivation by proteolytic enzymes from polymorpho-
nuclear granulocytes (e.g., PMN-elastase), could explain
Fig. 1. A: AT III activity in plasma before and 2 and 6 hr
after endotoxin infusion in endotoxin control rabbits (m),
and in rabbits receiving low (l) and high (j) LMWH plus AT
III. Values are expressed as the mean ± SEM percent of the
initial value before endotoxin infusion. *P < 0.05 and **P <
0.01 as compared with the endotoxin control group. B: Pro-
tein C activity in plasma before, and 2 and 6 hr after, endo-
toxin infusion in endotoxin control rabbits (m), and in rab-
bits receiving low (l) and high (j) LMWH plus AT III. Values
are expressed as the mean ± SEM percent of the initial value
before endotoxin infusion. *P < 0.05 and **P < 0.01 as com-
pared with the endotoxin control group.
LMWH and AT III in DIC in Rabbits 9
the uselessness of this treatment [21,22]. The results pre-
sented in a randomized study that compared the efficacy
of heparin vs. AT III in patients with DIC due to sepsis
or septic shock [23] would support our hypothesis, since
these authors obtained a much better outcome in the pa-
tients who were treated with AT III, especially in the
most severe cases, thus drawing attention to the useless-
ness of heparins when AT III stocks are exhausted.
However, the simultaneous addition of AT III and
LMWH improved the hemostatic profile (platelets, fi-
brinogen, protein C, AT III) as well as the renal fibrin
deposits in a LMWH dose-dependent manner. An earlier
study performed in our laboratory in the same model
showed that AT III given alone at the dose used in the
current study (20 U/Kg/hr/6 hr) had no beneficial effect
on renal fibrin deposition [14]. Nevertheless, the same
study showed that a much higher AT III dose did succeed
in reducing the intensity of kidney fibrin deposits, in
agreement with other models of endotoxin-induced DIC
that have reported a beneficial effect of AT III alone,
again at much higher doses than ours [10–13]. Therefore,
the improvement observed in the current study seems to
be due to the simultaneous infusion of both LMWH and
AT III. On the other hand, the treatment with UFH (10
IU/Kg/hr/6 hr) and AT III (20 U/Kg/hr/6 hr) in the same
earlier study [14] did not improve either the platelets or
the fibrinogen and, although a decrease in the kidney
fibrin deposits was achieved in such conditions (score 0.9
± 0.8), this reduction was less pronounced than the one
currently being assessed when LMWH and AT III are
used at the same doses (score 0). Moreover, it must be
remembered that the end point in the UFH and AT III
experiments was at 8 hr instead of at 24 hr. UFH and AT
III also decreased mortality, although again the endpoint
was at 8 hr. From these data, LMWH seems to be more
efficient than UFH in this model.
When AT III was given with the low-dose LMWH the
plasma AT III levels did not decrease with respect to
baseline. Furthermore, when this treatment was admin-
istered at high-dose LMWH the AT III levels were con-
tinuously increasing through the experiment. On the
other hand, the lower protein C consumption could be
explained in the light of the diminished thrombin forma-
tion; the lower amount of thrombin-thrombomodulin
complexes would prevent the rapid protein C activation
and subsequent exhaustion observed in the nontreated
rabbits. It seems to be clear that the reported decrease in
the kidney fibrin deposits, with the remarkable total ab-
sence of fibrin in the group of high dose LMWH and AT
III, is a consequence of the improvement in the hemo-
static profile. On one hand, this finding would be com-
patible with our previous studies [14] in which both the
simultaneous infusion of UFH and AT III and the ad-
ministration of a supratherapeutic dose of AT III suc-
ceeded in reducing the kidney fibrin deposition, presum-
ably as a consequence of maintaining suitable AT III
levels. A recent study in a guinea pig DIC model would
also support this idea, although it must be noted that the
causal agents were gram-positive bacteria [24]. On the
other hand, the strong correlation obtained between pro-
tein C and renal fibrin deposition would suggest an im-
portant pathophysiological role for this inhibitor. A re-
cent study in our laboratory infusing r-hirudin in endo-
toxin-induced rabbits also showed a strong positive
correlation between protein C consumption and renal fi-
brin deposits [25]. Moreover, an acquired protein C de-
ficiency correlated positively with the extent of the skin
lesion, in turn reflecting the severity of microvascular
thrombosis, has been reported in human septic patients
[26]. Taking these findings together, it is tempting to
speculate that protein C plays an etiologic role in micro-
thrombosis development, although the possibility that
this molecule is merely a sensitive and reliable DIC
marker cannot be excluded.
Mortality decreased in rabbits treated simultaneously
with LMWH and AT III in a LMWH dose-dependent
manner with respect to control animals. The fact that this
decrease was not statistically significant could be ex-
plained by the relatively low number of animals included
in the study. Nevertheless, the decrease from 70% to 20%
shows a tendency to an improved survival in the treated
rabbits.
Fig. 2. Score of fibrin deposition in
kidneys in endotoxin control group
and in rabbits receiving LMWH (low
and high dose) with and without AT
III. Score values are expressed as
mean ± SEM. *P < 0.01 and **P < 0.001
as compared with the endotoxin con-
trol group.
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When all the rabbits were divided into two groups,
survivors at 24 hr and nonsurvivors, significantly more
intense renal fibrin deposits as well as a significantly
higher consumption of platelets, fibrinogen, and protein
C in the nonsurvivor animals were reported. Among the
latter, the difference assessed in the protein C levels must
be underlined once more.
Finally, we want to say that the benefits of the simul-
taneous infusion of LMWH and AT III seem to be similar
to those obtained after the administration of r-hirudin in
the same rabbit DIC model [25].
CONCLUSIONS
In conclusion, simultaneous infusion of AT III and
LMWH improves the hemostatic profile and decreases
the renal fibrin deposits and mortality rate in this model
of endotoxin-induced DIC in rabbits. The fact that simi-
lar doses of LMWH infused alone do not have beneficial
effects shows that, in our model, LMWH needs an ex-
ogenous support of AT III to exert its action. On the other
hand, given that infusion of AT III alone at the current
dose had previously proven to be ineffective, it seems to
be clear that the inhibitor, when given at such dose, needs
an exogenous support of its cofactor to succeed effi-
ciently in improving the hemostatic profile. Moving to
the human therapeutical field, we suggest that the simul-
taneous infusion of LMWH and AT III would reduce the
amount of the inhibitor needed to be efficient, which is
interesting from the cost benefit point of view. Finally,
the observed correlations between fibrin deposits and he-
mostatic parameters as well as the comparison of such
parameter between nonsurvivor and survivor rabbits sug-
gest that protein C could play an important role in the
pathogenesis of endotoxin-induced DIC, although further
studies are required to assess this point.
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